This phase 2, multi-institutional clinical trial assesses whether patients with resected primary gastrointestinal stromal tumor receiving 5 years of adjuvant imatinib mesylate therapy have improved recurrence-free survival and overall survival compared with patients receiving a shorter duration of therapy in previous studies.
https://ift.tt/2PEh40e
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου